In case some of you were waiting for Apothecury’s take on the Glivec judgement, I was waiting for this piece that I did for the Sunday Economic Times to be published. In a nutshell, in the article I explain why, as far as India’s generics industry is concerned, the Glivec outcome is not really a new win but more like savouring the same victory twice over. You can read the piece here. (Please ignore the New Delhi dateline in the story, I still operate from Mumbai).
Pic courtesy photostream of 757Live on Flickr.
Apothecurry 
Was very good. How have you been Gauri?
Regards GNN
LikeLike
Thanks Mr Nayak. I am well. Hope the mental health magazine is doing good? Do stay in touch. My best to Mrs Nayak
LikeLike
As usual, superb post gauri. I agree, I think the outcome was expected given the Indian patent regime.
LikeLike
Thanks Gina.It is also worth noting that the IPA’s statement to the Glivec judgement was measured and stuck to outlining the facts of the case – no unnecessary rhetoric!
LikeLike